These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1931460)

  • 21. Phase II study of teniposide in small cell carcinoma of the lung.
    Pedersen AG; Bork E; Osterlind K; Dombernowsky P; Hansen HH
    Cancer Treat Rep; 1984 Oct; 68(10):1289-91. PubMed ID: 6098366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimetastasis effect of two derivatives of epiposophyllotoxin in mice.
    Cattan A; Pourny C; Carpentier Y; Cattan E; Barouh M
    Eur J Cancer (1965); 1976 Oct; 12(10):797-805. PubMed ID: 976288
    [No Abstract]   [Full Text] [Related]  

  • 23. Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro.
    Yalowich JC; Fry DW; Goldman ID
    Cancer Res; 1982 Sep; 42(9):3648-53. PubMed ID: 6179605
    [No Abstract]   [Full Text] [Related]  

  • 24. Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (etoposide and teniposide).
    Lönn U; Lönn S; Nylen U; Winblad G
    Cancer Res; 1989 Nov; 49(22):6202-7. PubMed ID: 2553248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.
    Issell BF; Tihon C; Curry ME
    Cancer Chemother Pharmacol; 1982; 7(2-3):113-5. PubMed ID: 7083450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VM26: phase I and II studies.
    Macbeth FR
    Cancer Chemother Pharmacol; 1982; 7(2-3):87-91. PubMed ID: 7044595
    [No Abstract]   [Full Text] [Related]  

  • 28. Synthesis and structure-activity relationships among glycosidic derivatives of 4'-demethylepipodophyllotoxin and epipodophyllotoxin, showing VM26- and VP16-213-like activities.
    Gupta RS; Chenchaiah PC; Gupta R
    Anticancer Drug Des; 1987 Aug; 2(1):1-12. PubMed ID: 3449081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives.
    Gordaliza M; García PA; del Corral JM; Castro MA; Gómez-Zurita MA
    Toxicon; 2004 Sep; 44(4):441-59. PubMed ID: 15302526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etoposide: four decades of development of a topoisomerase II inhibitor.
    Hande KR
    Eur J Cancer; 1998 Sep; 34(10):1514-21. PubMed ID: 9893622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay.
    Matsushima Y; Kanzawa F; Miyazawa N; Sasaki Y; Saijo N
    Anticancer Res; 1986; 6(5):921-4. PubMed ID: 3026235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Etoposide: VP-16].
    Dicato M
    Bull Soc Sci Med Grand Duche Luxemb; 1982; 119(2):15-8. PubMed ID: 7160031
    [No Abstract]   [Full Text] [Related]  

  • 35. Current development of podophyllotoxins.
    Canetta R; Hilgard P; Florentine S; Bedogni P; Lenaz L
    Cancer Chemother Pharmacol; 1982; 7(2-3):93-8. PubMed ID: 7044596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
    Locker GY; Lanzotti V; Khandekar JD; Sweet D; Shaw J; Bitran J; Gordon L; Krauss S; Johnson C
    Cancer Treat Rep; 1986 Feb; 70(2):307-8. PubMed ID: 3948195
    [No Abstract]   [Full Text] [Related]  

  • 37. Etoposide in small cell lung cancer resistant to prior chemotherapy.
    Asbury RF; Rubins J; Bennett JM
    Cancer Treat Rep; 1983 Oct; 67(10):951-2. PubMed ID: 6313187
    [No Abstract]   [Full Text] [Related]  

  • 38. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
    Kerrigan D; Pommier Y; Kohn KW
    NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
    Muss H; Bundy BN; DiSaia PJ; Twiggs LB
    Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose teniposide for refractory malignancies: a phase I study.
    de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
    Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.